Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
NYSE Owner Backs Polymarket With $2 Billion Bet

NYSE Owner Backs Polymarket With $2 Billion Bet

DailyCoinDailyCoin2025/10/08 09:17
By:DailyCoin

Intercontinental Exchange Inc. (ICE), a Fortune 500 company and the parent company of the world’s largest New York Stock Exchange (NYSE), announced plans to invest up to $2 billion in the crypto-based betting platform Polymarket, marking one of the most significant moves by a traditional financial institution into decentralized prediction markets.

The deal, announced Tuesday, values Polymarket at about $8 billion. Under the partnership, ICE will distribute Polymarket’s event-driven data to global clients, offering market sentiment insights drawn from real-world predictions. The two firms also plan to work together on tokenization projects.

Sponsored

“Together, we’re expanding how individuals and institutions use probabilities to understand and price the future,” said Polymarket CEO Shayne Coplan, emphasizing the firm’s focus on bridging traditional finance and emerging decentralized models. 

A Historic Step

Market analyst Binji says ICE’s $2 billion investment in Polymarket is more than a record-breaking crypto move, as it represents a shift in the very nature of markets.

He notes that the same infrastructure supporting $29 trillion in equities is now being applied to markets that trade belief and probability, not just traditional assets.

According to the analyst, financial markets are becoming participatory, data-driven, and socially powered, blending attention, sentiment, and real-time event data with traditional systems, all secured through blockchain-based trust and transparency.

Polymarket Rebounds After Regulatory Hurdles

Founded in 2020, Polymarket allows users to trade on the outcomes of events such as elections, sports, and global news. 

Its popularity surged during the 2024 U.S. presidential election cycle, when billions of dollars were wagered on political outcomes. 

The company previously faced regulatory hurdles after the Commodity Futures Trading Commission (CFTC) ordered it to block U.S. users in 2022. Polymarket recently re-entered the U.S. market by acquiring QCX, a registered derivatives exchange, after regulators closed a probe earlier this year.

Why This Matters

ICE’s $2 billion bet on Polymarket signals a turning point for crypto prediction markets, reflecting growing institutional confidence in decentralized finance. The move could accelerate the integration of blockchain-based data and tokenized assets into mainstream financial systems.

Delve into DailyCoin’s popular crypto news:
Ethena Labs Partners with UR Global, Brings USDe to Digital Banking
Key Shiba Inu’s Price Levels To Watch For Bounce Back

People Also Ask:

What is Polymarket?

Polymarket is a decentralized prediction market platform where users can trade on the outcomes of events, including elections, sports, and global news. It uses blockchain technology to ensure transparency and trust.

How does Polymarket work?

Users place positions based on the probability of an event happening. Market prices reflect collective sentiment, allowing participants to speculate and gain insights into real-world predictions.

Who can use Polymarket?

Polymarket is open to users globally, although U.S. access was restricted in 2022 due to regulatory issues. The platform has since re-entered the U.S. market by acquiring a registered derivatives exchange, QCX.

Why is Polymarket significant for investors?

Polymarket represents a new class of financial markets that blend traditional trading infrastructure with decentralized, data-driven, and socially powered systems, making it appealing to institutional investors like ICE.

How is Polymarket regulated?

Polymarket operates under blockchain-based protocols and complies with regional financial regulations where applicable. Its acquisition of QCX allows it to legally serve U.S. users as a registered derivatives exchange.

DailyCoin's Vibe Check: Which way are you leaning towards after reading this article?
Bullish Bearish Neutral
Market Sentiment
0% Neutral
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Anthropic files for IPO: lost $4.2 billion last year, revenue grew 12x to $4.6 billion, risk section warns of "threats to human survival"

Anthropic's IPO prospectus reveals that its spending on computing power and infrastructure will reach $7.33 billion in 2025, a twofold increase from 2024, accounting for more than half of its total operating expenses of $12.65 billion. The company plans to continue investing over $500 billion in the future. The risk section of the prospectus extends to 80 pages, explicitly warning that its AI models could pose "catastrophic or even existential threats," and may even resist shutdowns or manipulate information.

华尔街见闻•2026/09/29 01:01

Meta shocks Wall Street by hiring MongoDB CEO and makes a high-profile entry into enterprise AI business

Meta has established an enterprise AI division called "Meta Enterprise Platform," which Mark Zuckerberg described as "the next important pillar." MongoDB CEO CJ Desai has been recruited to lead it. Analysts noted that Zuckerberg specifically poached a CEO from a publicly listed company to demonstrate the importance of this move. Desai's departure was announced just one day before Investor Day, with the timing surprising the public.

华尔街见闻•2026/09/29 00:51

AstraZeneca invests $2 billion in Summit, optimistic about Akeso's Ivose

This 18.6% premium subscription is not only a substantial endorsement, but both parties will also deeply collaborate on the joint development of combination therapies such as ADCs. The core of this deal is Akeso's Ivonescimab—the world’s first PD-1/VEGF bispecific antibody, and so far the only drug to have surpassed "K-drug" in head-to-head trials on both PFS and OS endpoints. The median OS reached 30.8 months, compared to 22.6 months for "K-drug", representing a 27% reduction in risk of death.

华尔街见闻•2026/09/29 00:26